Bispecific antibodies have emerged as an important modality in oncology, although their broader application can be limited by manufacturing complexity...

As PD-1/PD-L1 x VEGF-targeted bispecific antibodies gain momentum in oncology, selecting the right preclinical models is becoming increasingly important. These...